Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 3, 2017, Pages 812-815

  Merli, Marco ^a,b   Galli, Laura ^a   Marinaro, Letizia ^c   Ariaudo, Alessandra ^c   Messina, Emanuela ^a,b   Uberti Foppa, Caterina ^a   Castagna, Antonella ^a,b   D'Avolio, Antonio ^c   Lazzarin, Adriano ^a,b   Bonora, Stefano ^c   Hasson, Hamid ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; FUSED HETEROCYCLIC RINGS; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA;

BLOOD; COINFECTION; COMBINATION DRUG THERAPY; COMPLICATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RILPIVIRINE; RNA, VIRAL; SIMEPREVIR; SOFOSBUVIR; VIRAL LOAD;

EID: 85026199243     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw492     Document Type: Article

References (14)

1. Chen T, Terrault N. Treatment of chronic hepatitis C in patientswith cirrhosis. Curr Opin Gastroenterol 2016; 32: 143-51.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
3. Ford SL, Gould E, Chen S et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013; 57: 5472-7.
4. D'Avolio A, Baietto L, Siccardi Met al. AnHPLC-PDAmethod for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma ofHIV-infected patients. Ther Drug Monit 2008; 30: 662-9.
5. Hoetelmans R, Van Heeswijk R, Kestens D et al. Effect of food andmultipledose pharmacokinetics of TMC278 as an oral tablet formulation: healthy volunteers. In: Abstracts of the Third IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005. Poster TuPe3.1B10. International AIDS Society, Geneva, Switzerland.
6. Lawitz E, Rodriguez-Torres M, Denning JM et al. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother 2013; 57: 1209-17.
7. Ouwerkerk-Mahadevan S, Vekar V, Simion A et al. The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with antiretroviral agents in healthy volunteers. In: Abstracts of IDWeek, San Diego, CA, 2012. Abstract 36620. Infectious Diseases Society of America, Arlington, VA, USA.
8. Zhang J, Hayes S, Sadler BM et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol 2015; 80: 502-14.
9. Antiviral Drugs Advisory Committee Meeting. Briefing Document: Simeprevir (TMC435) Treatment of Patients with Chronic Hepatitis C. http:// www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterial s/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371624.pdf.
10. Ouwerkerk-Mahadevan S, Simion A, Spittaels K et al. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment. J Hepatol 2013; 58 Suppl 1: S365. Abstract 887.
11. Branch RA. Drugs in liver disease. Clin Pharmacol Ther 1998; 64: 462-5.
12. Ogasawara K, Terada T, Katsura T et al. Hepatitis C virus-related cirrhosis is amajor determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 2010; 25: 190-9.
13. Margolis DA, Brinson CC, Smith GH et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 2015; 15: 1145-55.
14. Gubavu C, Prazuck T, Niang M et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother 2016; 71: 1046-50.